Exploiting Novel Protein Domain Architectures to Deliver Next-Generation Bispecific & Biparatopic Protein Drug Conjugates
Time: 11:30 am
day: Conference Day Two
Details:
- A suite of protein-drug conjugates (PDCs) have been developed which exploit small protein domain binders to deliver differentiated homogeneous conjugates
- Lead PDCs targeting ROR1 and ALPP/ALPPL2 have been engineered to provide enhanced delivery of payloads through utilization of bispecific and biparatopic architectures and cause sustained regressions in cancer models in vivo
- PDC target binders, payloads and conjugate formats chosen to provide differentiated patient selection strategies
